Hepatitis E Virus

By Targets:	HBV (2) HCV (3) Virus Protease (1) Apoptosis (1) Bacterial (1) Drug Metabolite (1) HIV (1) Parasite (1) SARS-CoV (1) Sodium Channel (1)
By Research Areas:	Cancer (2) Infection (7)

Targets Recommended: Hepatitis E Virus (HEV) HCV HBV Influenza Virus Dengue Virus Virus Protease Tomato Spotted Wilt Virus (TSWV)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N10543

5-O-(E)-p-Coumaroylquinic acid	HBV	Infection
5-O-(E)-p-Coumaroylquinic acid, a quinic acid derivative, is a potent phytochemical agent against **hepatitis B virus** .

HY-136266

HCV-IN-29	HCV	Cancer
HCV-IN-29 is a hepatitis C virus (HCV) inhibitor exacted from patent US8329159B2, compound 1e .

HY-I0727

Sofosbuvir impurity E	Drug Metabolite	Others
Sofosbuvir impurity E is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-128067

5-(N,N-Hexamethylene)-amiloride 2 Publications Verification Hexamethylene amiloride; HMA	Sodium Channel HIV Apoptosis	Infection Cancer
5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent Na ⁺/H ⁺ exchanger inhibitor, which decreases the intracellular pH (pH_i) and induces apoptosis in leukemic cells. 5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) is also an inhibitor of the *HIV-1 Vpu virus* ion channel** and inhibits mouse hepatitis virus (MHV) replication and human coronavirus 229E (HCoV229E) replication in cultured L929 cells with EC₅₀s of 3.91 μM and 1.34 μM, respectively .

HY-125728

Micrococcin P1	Bacterial Parasite HCV	Infection
Micrococcin P1 is a macrocyclic peptide antibiotic and is a potent hepatitis C virus (HCV) inhibitor with an EC₅₀ range of 0.1-0.5 μM . Micrococcin P1 has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Micrococcin P1 against *S. aureus* 1974149, E. faecalis 1674621 and S. pyogenes 1744264 are 2 μg/mL, 1 μg/mL and 1 μg/mL, respectively . Micrococcin P1 is also a potent inhibitor of the malaria parasite Plasmodium falciparum .

HY-N10830

(±)-Nirtetralin	Others	Infection
(±)-Nirtetralin is an isomer of Nirtetralin, which inhibits growth of **hepatitis E virus (HEV**) in HepaRG cells .

HY-P4029

HCV-1 e2 Protein (484-499)	HCV	Infection
HCV-1 e2 Protein (484-499) is a peptide consisting of 16 amino acids. HCV-1 e2 Protein (484-499) is derived from the envelope 2 protein of hepatitis C virus in the sera from individuals with antibodies to HCV .

HY-169410

SARS-CoV-2 3CLpro-IN-29	SARS-CoV Virus Protease	Infection
3CLPro-IN-3 (Compound A36) is an inhibitor for SARS-CoV-2 3CLpro with IC₅₀ of 51.3 nM. 3CLPro-IN-3 exhibits antiviral activity against human coronavirus 229E, OC43 and mouse hepatitis virus MHV .

HY-N12105

Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside	HBV	Infection
Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is an anti-hepatitis B virus (anti-HBV) agent. Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside inhibits HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) secretion on Hep G2.2.15 cell line, with IC₅₀ values of 1.67 and >2.15 mM, respectively .

Cat. No.	Product Name

HY-L073

*Anti-Hepatitis* C Virus Compound Library**	344 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 344 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

344 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 344 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Target	Research Area

HY-P4029

HCV-1 e2 Protein (484-499)	HCV	Infection
HCV-1 e2 Protein (484-499) is a peptide consisting of 16 amino acids. HCV-1 e2 Protein (484-499) is derived from the envelope 2 protein of hepatitis C virus in the sera from individuals with antibodies to HCV .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10543

5-O-(E)-p-Coumaroylquinic acid	Structural Classification Monophenols Phenols Spatholobus suberectus Dunn Plants Compositae	HBV
5-O-(E)-p-Coumaroylquinic acid, a quinic acid derivative, is a potent phytochemical agent against **hepatitis B virus** .

HY-N10830

(±)-Nirtetralin	Phyllanthus urinaria Linn. Structural Classification Source classification Lignans Euphorbiaceae Phenylpropanoids Plants	Others
(±)-Nirtetralin is an isomer of Nirtetralin, which inhibits growth of **hepatitis E virus (HEV**) in HepaRG cells .

HY-N12105

Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside	Structural Classification Source classification Lignans Phenylpropanoids Plants Schisandraceae Illicium henryi Diels.	HBV
Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is an anti-hepatitis B virus (anti-HBV) agent. Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside inhibits HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) secretion on Hep G2.2.15 cell line, with IC₅₀ values of 1.67 and >2.15 mM, respectively .

Species:	Virus (4) Human (2)
Tag:	His (5) Tag Free (1)
Source:	HEK293 (4) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P74183

	*E2/Envelope Protein, Hepatitis* C virus (AAC15723, HEK293, His)** HCV-1a E2 Protein; Hepatitis C Virus (serotype 1b, isolate HC-J4) Envelope/E2 Protein	Virus	HEK293
	E2/Envelope Protein, Hepatitis C virus (AAC15723, HEK293, His) is the recombinant Virus-derived E2/Envelope protein, expressed by HEK293 , with C-His labeled tag.

HY-P74184

	*E2/Envelope Protein, Hepatitis* C virus (BAA03581, HEK293, His)** Hepatitis C Virus (HCV) (serotype 1c,isolate HC-G9) E2 Protein (His Tag); HCV-1a E2 Protein	Virus	HEK293
	E2/Envelope Protein, Hepatitis C virus (BAA03581, HEK293, His) is the recombinant Virus-derived E2/Envelope protein, expressed by HEK293 , with C-His labeled tag.

HY-P74185

	*E2/Envelope Protein, Hepatitis* C virus (278a.a, HEK293, His)** Hepatitis C Virus (HCV) (serotype 1c,isolate HC-G9) E2 Protein (His Tag); HCV-1a E2 Protein	Virus	HEK293
	E2/Envelope Protein, Hepatitis C virus (278a.a, HEK293, His) is the recombinant Virus-derived E2/Envelope protein, expressed by HEK293 , with C-His labeled tag.

HY-P74899

	Envelope Glycoprotein E1 Protein, HCV (HEK293, His) HCV-E1 Protein; Hepatitis C Virus Envelope Glycoprotein E1 / HCV-E1 (subtype 1b, strain HC-J4) Protein	Virus	HEK293
	Envelope Glycoprotein E1 Protein, one of two subunits of the envelope glycoprotein found in the hepatitis C virus, is a type 1 transmembrane protein.It associates with envelope glycoprotein E2 as a noncovalent heterodimer, which mediates virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane.E1/E2 heterodimer binds host apolipoproteins.And it also binds to CD81 and activates the epithelial growth factor receptor (EGFR) signaling pathway.Envelope Glycoprotein E1 Protein, HCV (HEK293, His) is the recombinant Virus-derived Envelope Glycoprotein E1 protein, expressed by HEK293 , with N-His labeled tag.

HY-P702076

	RBCK1 Protein, Human RBCK1; RanBP-type and C3HC4-type zinc finger-containing protein 1; HBV-associated factor 4; Heme-oxidized IRP2 ubiquitin ligase 1; HOIL-1; Hepatitis B Virus X-associated protein 4; RING finger protein 54; RING-type E3 ubiquitin transferase HOIL-1; Ubiquitin-conjugating enzyme 7-interacting protein 3	Human	E. coli
	RBCK1 is an E3 ubiquitin protein ligase that cooperates with specific E2 enzymes such as UBE2L3/UBCM4 to transfer ubiquitin to substrates. It acts as an E3 ligase that oxidizes IREB2, relying on heme and oxygen for IREB2 ubiquitination. RBCK1 Protein, Human is the recombinant human-derived RBCK1 protein, expressed by E. coli , with tag free.

HY-P702077

	RBCK1 Protein, Human (His) RBCK1; RanBP-type and C3HC4-type zinc finger-containing protein 1; HBV-associated factor 4; Heme-oxidized IRP2 ubiquitin ligase 1; HOIL-1; Hepatitis B Virus X-associated protein 4; RING finger protein 54; RING-type E3 ubiquitin transferase HOIL-1; Ubiquitin-conjugating enzyme 7-interacting protein 3	Human	E. coli
	RBCK1 is an E3 ubiquitin protein ligase that cooperates with specific E2 enzymes such as UBE2L3/UBCM4 to transfer ubiquitin to substrates. It acts as an E3 ligase that oxidizes IREB2, relying on heme and oxygen for IREB2 ubiquitination. RBCK1 Protein, Human (His) is the recombinant human-derived RBCK1 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins